Raising the Bar for Clinical Cardiac Troponin Research Studies and Implementation Science

ver the past 3 decades, cardiac troponin (cTn) I and T have evolved as the preferred biomarkers for the detection of myocardial injury and in the appropriate setting to support the diagnosis of acute myocardial infarction (MI). 1 Almost all of the early data in this field were derived from observational studies including multiple key secondary analyses from acute coronary syndrome trials supporting their use. 2 Over time, analytic advancements brought by high-sensitivity (hs) cTn assays enabled the reliable measurement of very low cTn concentrations that allowed the development of various MI risk stratification approaches.